Presented By: DCMB Seminar Series
DCMB / CCMB Weekly Seminar Series
Marcin Cieslik, "Bridging Tumor Genotypes and Phenotypes Through Proteogenomics"
Abstract:
Methodological breakthroughs over the past decades have repeatedly revolutionized genomic and proteomic profiling of human tumors. Using RNA sequencing and mass-spectrometry it has now become possible quantify the transcriptional and translational outputs of thousands of tumor samples. These data provide a link between cellular phenotypes and their molecular underpinnings, such as mutations. In the context of cancer, this link represents an opportunity to dissect the complexity and heterogeneity of tumors and to discover new biomarkers or therapeutic strategies. The National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium (CPTAC) was established to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome and genome analysis, or proteogenomics. In my talk I will review the rationale, methodology and translational impact of proteogenomic profiling of cancer, and detail the contributions of the University of Michigan Proteogenomic Data Analysis Center towards efforts to unravel the genetic and phenotypic complexity of multiple common and rare human cancers.
https://umich-health.zoom.us/j/93929606089?pwd=SHh6R1FOQm8xMThRemdxTEFMWWpVdz09
Short Bio:
Marcin Cieslik is an assistant professor in the Departments of Pathology and Computational Medicine and Bioinformatics at the University of Michigan. His lab's research aims to further the discovery, understanding, and clinical translation of genomic underpinnings of cancer. His research group specializes in the development of computational and statistical methods for the analysis of large-scale sequencing data to understand genomic and proteomic mechanisms related to cancer. Currently, their research focuses on discovering genetic and regulatory mechanisms of cancer immune evasion and understanding oncogenic mechanisms through integrative analyses of cancers genomes and proteomes.
Methodological breakthroughs over the past decades have repeatedly revolutionized genomic and proteomic profiling of human tumors. Using RNA sequencing and mass-spectrometry it has now become possible quantify the transcriptional and translational outputs of thousands of tumor samples. These data provide a link between cellular phenotypes and their molecular underpinnings, such as mutations. In the context of cancer, this link represents an opportunity to dissect the complexity and heterogeneity of tumors and to discover new biomarkers or therapeutic strategies. The National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium (CPTAC) was established to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome and genome analysis, or proteogenomics. In my talk I will review the rationale, methodology and translational impact of proteogenomic profiling of cancer, and detail the contributions of the University of Michigan Proteogenomic Data Analysis Center towards efforts to unravel the genetic and phenotypic complexity of multiple common and rare human cancers.
https://umich-health.zoom.us/j/93929606089?pwd=SHh6R1FOQm8xMThRemdxTEFMWWpVdz09
Short Bio:
Marcin Cieslik is an assistant professor in the Departments of Pathology and Computational Medicine and Bioinformatics at the University of Michigan. His lab's research aims to further the discovery, understanding, and clinical translation of genomic underpinnings of cancer. His research group specializes in the development of computational and statistical methods for the analysis of large-scale sequencing data to understand genomic and proteomic mechanisms related to cancer. Currently, their research focuses on discovering genetic and regulatory mechanisms of cancer immune evasion and understanding oncogenic mechanisms through integrative analyses of cancers genomes and proteomes.
Related Links
Explore Similar Events
-
Loading Similar Events...
